The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients

Lupus

Volumn 9, Issue 2, 2000, Pages 92-95

  Toubi, Elias ^a,b   Rosner, I ^a   Rozenbaum, M ^a   Kessel, A ^a   Golan, T D ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Antimalarials; Hydroxychloroquine; Quinacrine; SLE

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; HYDROXYCHLOROQUINE; MEPACRINE; METHOTREXATE; PREDNISONE;

ADULT; AGRANULOCYTOSIS; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; REMISSION; SKIN DISCOLORATION; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034104878     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828082     Document Type: Article

References (21)

1. Payne JF. A postgraduate lecture on lupus erytematosus. Clin J 1894; 4: 223-229.
2. Office of the Surgeon Genera. Circular letter no. 153: the drug treatment of malaria, suppressive and clinical. JAMA 1943; 125: 205-208.
3. Page E. Treatment of lupus erythematosus with mepacrine. Lancet 1951; 2: 755-758.
4. Dubois EL. Management of discoid and systemic lupus erythematosus. In: Dubois EL. Lupus Erythematosus, 2ed. Los Angeles: University of Southern California Press, 1974. pp. 537-613.
5. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989; 18: 282-297.
6. The Canadian hyroxychloquine study group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in SLE. New Engl J Med 1991; 324: 150-154.
7. Langevitz P, Kaplinsky N, Ehrenfeld M et al. Intractable RA-treatment with combined methotrexate, azathioprine and hydroxychloroquine. Br J Rheumatol 1989; 38: 271-272.
8. Wallace DJ. Antimalarial drugs. In: Wallace DJ, Hahn BH (eds). Dubois' Lupus Erythematosus, 4th ed. Philadelphia: Lea and Febiger 1993, pp. 563-573.
9. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243-263.
10. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 1271-1277.
11. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
12. Nguyen TQ, Capra JD, Sontheimer RD. 4-Aminoquinoline antimalarials enhance UVB induced c-jun transcriptional activation. Lupus 1998; 7: 148-153.
13. Koranda FC. Antimalarials. J Am Acad Dermatol 1981; 4: 650-655.
14. Cutler DJ. Possible mechanisms of action of antimalarials in rheumatic disease. Agent Action Suppl 1993; 44: 139-143.
15. Fox RI. Mechanisms of action of Hydroxychloroquine as an anti-rheumatic drug. Semin Arthritis Rheum 1993; 23 (Supp) 1: 82-91.
16. Potvin F, Petitclec E, Marceau F, Poubelle PE. Mechanisms of action of antimalarials in inflammation: Induction of apoptosis in human endothelial cells. J Immunol 1997; 158: 1872-1879
17. Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of antibodies in cultured keratinocytes of SLE patients after UVB/UVA irradiation. J Clin Invest 1992; 90: 1067-1076.
18. Carmichael AJ. Hydroxychloroquine: a guide to usage. J Dermatol Treat 1992; 3: 103-106.
19. Lanham JG, Hughes GR. Antimalarial therapy in SLE. Clin Rheum Dis 1982; 8: 279-298.
20. Weiss JS. Antimalarial medications in dermatology. A review. Dermatol Clin 1991 9: 377-385.
21. Spikes JD. Photosensitizing properties of quinine and synthetic antimalarials. J Photocehem Photobiol B: Biol 1998; 42: 1-11.